#T1D #DiabetesCare #CellTherapy #Biopharma #DrugDevelopment #PharmaStrategy #LifeSciences To view or add a comment, sign in 10,837 followers More from this author StratAI: Moving Drug Discovery Beyond the Linear Screening Funnel Alan Nafiev 3w Oral Peptides Need More Than Potency: Balancing Affinity & Permeability using AI-Guided Multi-Objective Optimization Alan Nafiev 2mo Docking in Challenging Conditions: Physics-Based vs AI-Driven Approaches Alan Nafiev 4mo
BPC-157 is most commonly used for soft-tissue injury recovery (tendons, ligaments, muscle), chronic tendinopathy, joint discomfort, gut health concerns, and post-surgical tissue repair
The problem with intestinal permeability occurs when the gaps between the delicate cells in the gut lining get a little too lax, and bigger openings allow bigger molecules of undigested food, toxins, even pathogens like parasites and the natural microbes in our intestines to escape into the bloodstream, forcing our detox and immune systems to work harder
There is a rise in R&D activities in biopharmaceuticals and drug discovery to fulfill the need for new and improved drugs
Laboratory researchers also rely on GSH as a critical component in cell culture media to regulate redox conditions, allowing for the precise study of oxidative stress, drug metabolism, and cellular signaling pathways
